US30052C1071 - EOLS - A2JDYX (XNMS)
EVOLUS INC Acción
10,89 USD
Cotizaciones actuales de EVOLUS INC
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria | Variación diaria % |
---|---|---|---|---|---|---|
NASDAQ |
EOLS
|
USD
|
20.12.2024 22:00
|
10,89 USD
| 10,87 USD | 0,18 % |
London |
0K16.L
|
USD
|
19.12.2024 20:14
|
10,74 USD
| 11,08 USD | -3,11 % |
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | -5,39 % | -13,57 % | -34,20 % | 3,22 % | 9,34 % | -11,75 % |
Profil de l'entreprise pour EVOLUS INC Action
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Données de l'entreprise pour EVOLUS INC Action
Nom EVOLUS INC
Société Evolus, Inc.
Symbole EOLS
Site web https://www.evolus.com
Marché d'origine
NASDAQ/NMS (GLOBAL MARKET)
WKN A2JDYX
ISIN US30052C1071
Type de titre Action
Secteur Healthcare
Industrie Drug Manufacturers - Specialty & Generic
PDG Mr. David Moatazedi
Capitalisation boursière 996 Mio
Pays États-Unis d'Amérique
Devise USD
Employés 0,3 T
Adresse 520 Newport Center Drive, 92660 Newport Beach
Date d'introduction en bourse 2018-02-08
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | EVL.F |
London | 0K16.L |
NASDAQ | EOLS |
More Shares
Investors who EVOLUS INC hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.